Therefore, to further explore the efficacy and safety of RC48 in real-world clinical practice, this study retrospectively analyzed the clinical records of 89 patients with metastatic BC, either HER2-positive or HER2-low-expression, treated with RC48 at Nanjing Medical University First Affiliated Hospital and Jiangsu Cancer Hospital. The gene discussed is ERBB2; the disease is breast cancer.